References
- Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin. Biochem. 37(7), 541–548 (2004).
- Mani T, Wang F, Knabe WE et al. Small-molecule inhibition of the uPAR.uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. Bioorg. Med. Chem. 21(7), 2145–2155 (2013).
- Hu XW, Duan HF, Gao LH et al. Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor. Cancer Biol. Ther. 7(5), 651–659 (2008).
- Tsutsumi S, Beebe K, Neckers L. Impact of heat-shock protein 90 on cancer metastasis. Future Oncol. 5(5), 679–688 (2009).
- Stellas D, El Hamidieh A, Patsavoudi E. Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol. 11, 51 (2010).
- Sidera K, El Hamidieh A, Mamalaki A, Patsavoudi E. The 4C5 cell-impermeable anti-HSP90 antibody with anti-cancer activity, is composed of a single light chain dimer. PLoS ONE 6(9), e23906 (2011).
- Chaurasia P, Mezei M, Zhou MM, Ossowski L. Computer aided identification of small molecules disrupting uPAR/α5β1 – integrin interaction: a new paradigm for metastasis prevention. PLoS ONE 4(2), e4617 (2009).
- Velasco-Velázquez M, Jiao X, De La Fuente M et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 72(15), 3839–3850 (2012).
- Rastelli L, Valentino ML, Minderman MC et al. A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo. Int. J. Oncol. 39(2), 401–408 (2011).
- Koh YJ, Kim HZ, Hwang SI et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18(2), 171–184 (2010).
- Huang Y, Zhou Y, Wong HC et al. Calmodulin regulates Ca2+-sensing receptor-mediated Ca2+ signaling and its cell surface expression. J. Biol. Chem. 285(46), 35919–35931 (2010).
- Wang H, Gao X, Yang JJ, Liu ZR. Interaction between p68 RNA helicase and Ca2+-calmodulin promotes cell migration and metastasis. Nat. Commun. 4, 1354 (2013).
- Quintela-Fandino M, Arpaia E, Brenner D et al. HUNK suppresses metastasis of basal type breast cancers by disrupting the interaction between PP2A and cofilin-1. Proc. Natl Acad. Sci. USA 107(6), 2622–2627 (2010).
- Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 32(9), 1073–1081 (2013).
- Bitler BG, Menzl I, Huerta CL et al. Intracellular MUC1 peptides inhibit cancer progression. Clin. Cancer Res. 15(1), 100–109 (2009).
- Jubb H, Higueruelo AP, Winter A, Blundell TL. Structural biology and drug discovery for protein–protein interactions. Trends Pharmacol. Sci. 33(5), 241–248 (2012).
- Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces. Nature 450(7172), 1001–1009 (2007).
- Lo Conte L, Chothia C, Janin J. The atomic structure of protein–protein recognition sites. J. Mol. Biol. 285(5), 2177–2198 (1999).
- White AW, Westwell AD, Brahemi G. Protein–protein interactions as targets for small-molecule therapeutics in cancer. Expert Rev. Mol. Med. 10, e8 (2008).
- Stelzl U, Wanker EE. The value of high quality protein–protein interaction networks for systems biology. Curr. Opin. Chem. Biol. 10(6), 551–558 (2006).
- Chuang HY, Lee E, Liu YT, Lee D, Ideker T. Network-based classification of breast cancer metastasis. Mol. Syst. Biol. 3, 140 (2007).